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ABSTRACT
Resistant hypertension is, by definition, a challenge to most physicians treating hypertension. Renal
sympathetic denervation has shown promising early results in treating this condition. The SYMPLICITY
HTN-3 is the most recent trial to report the effects of this technique on resistant hypertension. This
review discusses this study and its surprising neutral results before ending with an overview of key
lessons learned.
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SYMPLICITY HTN-11 and SYMPLICITY HTN-22 demonstrated that renal denervation (RDN) could achieve
a significant reduction in office blood pressure in patients with resistant hypertension. At 36 months,
88 patients in SYMPLICITY HTN-1, a proof-of-concept first-in-man registry, achieved a 32/14mmHg
reduction in blood pressure from baseline. The more robust randomised SYMPLICITY HTN-2 trial
showed a 33/11mmHg drop in blood pressure against control. These positive results, supported by
published data on thousands of other patients, added to the enthusiasm for this procedure.3 There
were few who doubted that RDN deserved a place in the hypertension specialist’s armoury and
thousands of procedures had already been performed mainly in Europe when SYMPLICITY HTN-3 was
launched as a prerequisite for registration of renal denervation in the United States (US) according to
the stringent standards of the Food and Drug Administration.
SYMPLICITY HTN-3
SYMPLICITY HTN-3 was designed as a prospective, randomised, single-blind, sham-controlled trial. It
compared the effect of RDN using the Symplicitye catheter (Medtronic, Minneapolis, MN-USA) against
a sham procedure (renal angiography) in 535 patients.4 There was unequal randomisation, 2:1
(RDN:control). The study was conducted across 88 centres in the United States between October 2011
and May 2013.
The inclusion and exclusion criteria are illustrated in Table 1. In contrast to SYMPLICITY HTN-2,
patients not only had initial evidence of a persistently elevated systolic blood pressure $160mmHg
in an office measurement but also had an elevated 24hr ambulatory systolic blood pressure
($135mmHg) two weeks later.
The primary efficacy endpoint was defined as a change in office systolic blood pressure at 6 months.
A primary safety composite endpoint consisting of mortality, end-stage renal failure and need for renal
artery intervention amongst others was included. Change in 24hr ambulatory systolic blood pressure
was a secondary endpoint. The study was powered to show a superiority margin of 5mmHg or greater
in office systolic blood pressure and 2mmHg or greater in ambulatory systolic blood pressure.
At baseline, patients were on an average of five anti-hypertensive medications with four of these
being at maximally tolerated doses and these proportions did not change significantly at the 6 month
follow-up. Blinding was considered to be adequate with an index score .0.5.
RESULTS
There was no difference between the two groups in the change in office systolic blood pressure at
6 months:214.13^ 23.93mmHg (RDN group) vs211.74^ 25.94mmHg (sham-procedure) representing
a between group change of 22.39mmHg (p ¼ 0.26). There was also no difference with respect to
ambulatory systolic blood pressure (26.75^ 15.11mmHg vs 24.79^ 17.25mmHg, p ¼ 0.98).
Subgroup analysis showed RDN may have been better at lowering blood pressure in non-black
individuals and those less than 65 years of age. However, these changes were not found to be
significant after adjusting for multiple comparisons.
Table 1. Key inclusion and exclusion criteria of the SYMPLICITY HTN-3 trial.
Inclusion Criteria Exclusion Criteria
Office SBP $160mmHg on two clinic
visits two weeks apart
Ineligible renal artery anatomy (main renal artery ,4mm or
with ,20mm treatable length; multiple renal arteries;
renal artery stenosis (.50%), previous renal artery intervention)
On stable maximally tolerated doses of
3 or more antihypertensive
medications including a diuretic
eGFR , 45ml/min/1.73m2
24hr ABPM SBP ,135mmHg
Symptomatic postural hypotension
Other conditions (including primary
pulmonary hypertension, type 1 diabetes, severe valve stenosis,
acute coronary syndrome or stroke in last 6 months)
SBP – systolic blood pressure; eGFR – estimated glomerular filtration rate; ABPM – ambulatory blood pressure monitor.
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The study did achieve its primary safety endpoint (composite of death, end-stage renal disease,
embolic events resulting in end-organ damage, renovascular complications, or hypertensive crisis at
1 month or new renal-artery stenosis of more than 70% at 6 months), showing no difference between
the groups (1.4% vs 0.6%; p ¼ 0.67).
DISCUSSION
SYMPLICITY HTN-3 was the best designed and largest randomised trial of RDN in resistant hypertension
to date and demonstrated that RDN achieved a reduction of blood pressure in patients with resistant
hypertension that was large in absolute terms but rendered non-significant when compared to the
equally large drop of blood pressure in the sham group.
Before we ring the death knell on RDN we must first consider the explanations for this surprising
outcome. These explanations fall in to two main camps: the detractors’ camp who argues that RDN is
truly ineffective at lowering blood pressure and we have been misled by earlier trials in to believing this
novel therapy could eradicate resistant hypertension. For the supporters’ camp, the argument is that
RDN is in principle an effective treatment but that there were factors in this trial which erroneously led
to a negative conclusion.
To address the first camp we need to consider the differences between SYMPLICITY HTN-3 and the
first two SYMPLICITY HTN trials. SYMPLICITY HTN-3 required that resistant hypertension be confirmed on
ambulatory blood pressure monitoring. The value of ambulatory blood pressure monitoring cannot
be over-emphasized. In a cohort of 8295 patients classified as having resistant hypertension based
on office readings alone, a staggering 37.5% of subjects were reclassified as having white coat
hypertension after ambulatory monitoring.5 SYMPLICITY HTN-2 did not require ambulatory
measurements and hence may have recruited individuals with white coat hypertension. The second
important difference is that SYMPLICITY HTN-3 included a single-blinded sham procedure where the
earlier SYMPLICITY HTN trials did not. Unblinded patients and blood pressure assessors can introduce
important biases. Health care professionals assessing office blood pressure may alter the manner in
which they measure and record blood pressure to be more optimistic after their patient has undergone
RDN and on the patient’s part, they may become more compliant with standard medical therapy.3,6 The
combination of these two factors and the recruitment of some white coat hypertensives may have led
to such a large drop in blood pressure in SYMPLICITY HTN-2 which would have not have been seen had
there been a blinded sham procedure and ambulatory blood pressure monitoring at recruitment.3
The supporters’ camp emphasises the factors in SYMPLICITY HTN-3 which could have falsely lead to a
negative result. After all it is not only the earlier SYMPLICITY HTN studies which provided support for this
strategy but also the preclinical data showing the role of the renal sympathetic nerves both in
hypertension7 and heart failure.8 One factor which may have led to a falsely negative study is the
uncertainty whether the ablations were technically successful. All three SYMPLICITY HTN trials used the
same catheter: the single electrode Medtronic Symplicitye system (Figure 1). The single electrode
system requires manipulation to apply energy in a helical pattern to the superior, inferior and lateral
(anterior and posterior) walls of the renal artery (Figure 1). Technically, this can be difficult to achieve,
not least because there is no intra-procedure marker of success and it is difficult to distinguish between
an anterior and posterior position on fluoroscopy.9
It is possible that the SYMPLICITY HTN-2 trialists (non-US) who had better experience of using
the device were able to perform more effective renal denervation than the US operators in SYMPLICITY
HTN-3. Only 26 interventionists out of 111 in SYMPLICITY HTN-3 had performed 5 or more denervations.
This could explain some of the 19mmHg discrepancy in the fall of systolic blood pressure in the
denervation arms between SYMPLICITY HTN-2 and 3.
The final contribution to the failure of SYMPLICITY HTN-3 is the large drop in blood pressure seen in
the sham arm. The SYMPLICITY HTN-2 control arm actually showed an increase in systolic blood
pressure of 1 ^ 21mmHg (Figure 2). Thus if it had not been for the large drop in blood pressure in the
sham group (211.7 ^ 25.9mmHg), SYMPLICITY HTN-3 would have demonstrated the predicted
difference of 10mmHg. However, we cannot attribute the failure of SYMPLICITY HTN-3 to an “aberrant”
drop in blood pressure in the sham arm because although uncommon, such a large decrease in blood
pressure in the control arm of a trial is not unique to SYMPLICITY HTN-3. The ASPIRANT study was a
randomised, multi-centre, double-blind, placebo controlled trial of spironolactone in patients with
resistant hypertension (n ¼ 117).10 Though it recruited patients whose average blood pressure was
lower than that of the SYMPLICITY HTN-3 cohort, it too demonstrated a large placebo effect of
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28.1 ^ 14.8mmHg (Figure 2) but unlike SYMPLICITY HTN-3 it showed that spironolactone significantly
lowered systolic blood pressure beyond this placebo effect. Placebo effects do abate with time and
conversely RDN effects on blood pressure have been shown to increase with time.11 SYMPLICITY HTN-3
reported only blood pressure changes at 6 months. It would be of interest to review the 12-month
findings. Patient selection is also extremely important. Expecting RDN to be a panacea for patients of all
age, race and sex was probably too simplistic and a consequence of our incomplete understanding of
the mechanism of the antihypertensive effect of RDN therapy. If black patients were excluded from
analysis, the difference in systolic ambulatory blood pressure was greater than 6mmHg and we know
that black patients have a worse response than white hypertensives to beta blockers and















Office SBP at baseline
(mean±SD)
Difference between groups
178±18 178±16 180±16 180±17 155±10 154±12
p<0.0001 p=0.26 p=0.001








Figure 2. A graph summarising the effect sizes of active and comparator in three contemporary trials of resistant
hypertension.
Treat distal to proximal
≥5 mm
spacing
Figure 1. Renal Denervation. The Symplicitye Catheter is abutted to the renal artery wall using fluoroscopic
guidance. Ablations are applied as shown in a helical pattern including at least one of each anterior, posterior,
superior and inferior positions.
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Determining which of these camps is correct is important not only for the future of RDN in
hypertension but also in its application to other conditions such as heart failure. If the problem is
technical (incomplete denervation) then more effective technology using multi-electrode catheters in
experienced hands should lead to better outcomes in future trials of RDN. Another problem may be
patient selection; none of the SYMPLICITY HTN trials used evidence of a raised sympathetic tone as an
inclusion criterion.
WHAT HAVE WE LEARNED?
Despite SYMPLICITY HTN-3 being a well-designed study, a number of uncertainties have arisen which
prevent us from asserting that denervation is definitely ineffective at treating resistant hypertension.
We can learn some lessons from the design of the earlier SYMPLICITY HTN trials which both promoted
the use of RDN but have now left us with some uncertainty. The first simple lesson is the importance of
using ambulatory blood pressure to accurately diagnose resistant hypertension and exclude those with
white coat hypertension. Another lesson learned is the importance of blinding and a sham procedure
even if this carries risk to those in the sham arm because the small risk in a small number of patients
early in development can be justified by limiting exposure of a larger number of patients to the
procedure later in development if it ultimately fails to show a benefit.
A final comment is on the need to develop a method to confirm incomplete or ineffective renal
denervation. This is a critical uncertainty which is essential to determine whether it is the therapy which
is ineffective or the technique of achieving denervation is ineffective. Catheters have now been
developed with multiple electrodes, balloon mounting and irrigation. If it is ultimately shown that
incomplete denervation was the downfall of SYMPLICITY HTN-3 then these new technologies may be
the saviour of RDN.
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